Glucagon like peptide 1 analogs are effective therapeutics for the management and treatment of type 2 diabetes. They mimic the effects of endogenous glucagon-like peptide-1 (GLP-1), a peptide produced in the gut and one of the key incretin hormones, which has multiple effects like stimulating insulin secretion, reducing glucagon output, increasing satiety and slowing gastric emptying. Glucagon like peptide 1 analogs offer advantages like negligible risk of hypoglycemia, helping patients achieve glycemic control along with modest weight reduction and low risk of side effects like nausea. The global Glucagon Like Peptide 1 Analogs Market is estimated to be valued at US$ 11.87 Bn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of diabetes has been a key growth driver for the GLP-1 analogs market. According to the International Diabetes Federation, around 537 million adults were living with diabetes in 2021 globally and the number is projected to rise to 643 million by 2030 and 783 million by 2045. GLP-1 analogs are an effective alternative for patients failing on conventional anti-diabetic regimens and this growing diabetes patient pool requiring advanced therapeutics has boosted the demand for GLP-1 receptor agonists. The promising clinical profile of GLP-1 analogs with documented cardiovascular benefits has further increased their adoption over other anti-diabetic agents.
Segment Analysis
The global glucagon like peptide 1 analogs market is dominated by twice-daily GLP-1 receptor agonists sub segment due to its greater efficacy and continuity in controlling blood glucose levels over a longer period. These sub segment drugs help control post-prandial and fasting plasma glucose in patients with type 2 diabetes.
Key Takeaways
The global glucagon like peptide 1 analogs market growth is expected to witness high growth over the forecast period. Regionally, North America dominated the market in 2023 due to high prevalence of diabetes and increasing awareness and adoption of GLP-1 receptor agonist drugs in the region. Europe was the second largest regional market due to rising geriatric population and increasing healthcare expenditure in European countries.
Regional analysis
North America is expected to continue dominating the glucagon like peptide 1 analogs market during the forecast period, growing at a CAGR of 7.5%. This is attributed to rising incidence of diabetes, growing adoption of advanced treatment options, and presence of major players in the region. Europe is anticipated to be the second largest regional market growing at a CAGR of 8.2% between 2023-2030.
Key players
Key players operating in the glucagon like peptide 1 analogs market are Koru Pharmaceuticals Co. LTD, Galderma Laboratories L.P., and DERMEDICS International. Koru Pharmaceuticals Co. LTD offers GLP-1 receptor agonist drugs for type 2 diabetes treatment. Galderma Laboratories L.P. manufactures injectable medications for glucose regulation. DERMEDICS International provides dermatological and aesthetic solutions.
Get more insights on this topic: https://www.newsstatix.com/analogs-market-industry-insights-trendsanalogs-market-2023-2030/
